The DEK oncoprotein is upregulated by multiple leukemia-associated fusion genes.

Sandén, Carl; Jernmark Nilsson, Helena; Gullberg, Urban

Published in:
Blood Cells, Molecules & Diseases

DOI:
10.1016/j.bcmd.2014.11.014

2015

Link to publication

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
LETTER TO THE EDITOR

The DEK oncoprotein is upregulated by multiple leukemia-associated fusion genes

To the Editor

The DEK oncoprotein is ubiquitously expressed with multiple roles in epigenetic and transcriptional regulation. It is an architectural protein that contributes to heterochromatin integrity but also binds to transcriptionally active chromatin and has been shown to both promote and repress gene transcription in different genetic contexts [1, 2]. On a cellular level, DEK has been implicated in multiple cancer-related processes. Overexpression of DEK promotes cellular proliferation whereas depletion reduces proliferation and promotes differentiation. The cellular lifespan of HeLa cells is prolonged by overexpression of DEK and, conversely, treatment with shRNA against DEK leads to cellular senescence [3]. DEK also protects against cell death. Knockdown of DEK increases both p53-dependent and – independent apoptosis as well as the sensitivity to apoptotic agents such as etoposide [4, 5]. The importance of DEK in oncogenesis has been convincingly demonstrated by the finding that overexpression of DEK promotes cellular transformation in both cellular systems and mouse models [6]. Intriguingly, tumor cells appear to be more sensitive to reductions in DEK expression than normal cells, suggesting that DEK may be a potential target for cancer therapy [6].

The DEK oncogene is commonly upregulated in many cancers and a partner of the (6;9) chromosomal translocation, which leads to the formation of the fusion gene DEK-NUP214 in a subset of acute myeloid leukemia [3]. However, the underlying mechanisms of the overexpression are still unknown and the only factors known to regulate DEK expression are
the transcription factors E2F, YY1 and NF-Y, which promote transcription of the *DEK* gene by binding to defined sites in its promoter. The expression of DEK has long been considered upregulated also in AML, based on two studies using quantitative PCR analysis to demonstrate overexpression in cohorts of 15 and 41 patients [7, 8]. However, in a recent study in this journal, Logan *et al* showed similar expression levels in normal and malignant hematopoietic cells in an *in silico* analysis of a large pre-existing dataset, verified by tissue microarray [9].

To functionally address the question of DEK expression during leukemogenesis, we examined if the protein levels are affected by fusion proteins known to cause the disease. Thus, we expressed four of the most common leukemia-associated fusion proteins (AML1-ETO, BCR-ABL1, NUP98-HOXA9 and PML-RARα) in human primary hematopoietic cells by viral transduction and analyzed the DEK expression. Cells were isolated from umbilical cord blood using the Indirect CD34 MicroBead Kit from Miltenyi Biotec, after informed consent from donors. The cells were then transduced with viruses encoding the fusion gene and an IRES-driven marker gene coding for green fluorescent protein. Following sorting of successfully transduced cells by FACS, the cells were grown in StemSpan SFEM medium supplemented with 20% fetal bovine serum and the CC100 cytokine mix, all from Stemcell Technologies. After 6 days, total protein was extracted and analyzed for DEK expression by western blot (anti-DEK, BD Transduction Laboratories).

The results show that several of the fusion proteins cause an increase in DEK protein expression. Both NUP98-HOXA9 and BCR-ABL1 significantly upregulated DEK and the same trend was observed for AML1-ETO but not PML-RARα (Figure 1). Since DEK levels can be affected by cellular proliferation and associated factors such as E2F, we next examined
whether the increased DEK expression was the result of an increase in proliferation rate. Here, we observed the same proliferation patterns that have been previously described for primary CD34+ cells expressing these fusion genes. Namely, that BCR-ABL1 but not AML1-ETO, NUP98-HOXA9 or PML-RARα confers a pro-proliferative effect during 10 days of culture (Figure 2). We thus conclude that the upregulation of DEK is not secondary to an increase in proliferation. However, it should be noted that both of the fusion genes which increase DEK expression promote proliferation when the cells are cultivated for an extended period of time. It is thus possible that upregulation of DEK is linked to proliferation in that it precedes rather than follows a proliferative effect.

Although no studies have demonstrated an effect of NUP98-HOXA9 on either of the known DEK regulators E2F, YY1 and NF-Y, the possibility that the regulation is mediated by one of these factors cannot be excluded. However, it is also possible that the upregulation occurs through a pathway that is yet to be defined. Regardless, our findings represent a novel effect of BCR-ABL1 and NUP98-HOXA9 on DEK expression and suggest that DEK could mediate leukemogenic functions of these fusion genes. These results also suggest that upregulation of DEK is not an initiating event during leukemogenesis but rather secondary to the expression of oncogenes such as BCR-ABL1 and NUP98-HOXA9.

Acknowledgements

The authors would like to thank Dr Thoas Fioretos at the Department of Clinical Genetics at Lund University for kindly providing the BCR-ABL1 fusion gene and Dr Nabeel Yaseen at Washington University School of Medicine for kindly providing the AML1-ETO, NUP98-HOXA9 and PML-RARα fusion genes.
Conflict of interest

The authors have no conflict of interest to disclose.

References

Carl Sandén*

Helena Jernmark Nilsson

Urban Gullberg

Department of Hematology, Lund University, Lund, Sweden

*Corresponding author at: Department of Hematology, Lund University, BMC B13, Klinikgatan 26, 22184, Lund, Sweden. Telephone: +46-46-2220731. E-mail address: carl.sanden@med.lu.se.
Figure legends

Figure 1. DEK is upregulated by the expression of leukemia-associated fusion genes. (A) Western blot showing the expression of DEK protein 6 days after sorting of primary CD34+ cells transduced with leukemia-associated fusion genes. Expression of histone H3 is used as an equal loading control. One representative experiment out of five. (B) Expression of DEK protein, relative to the expression in cells transduced with empty vector. Mean values were calculated from five independent experiments. Error bars represent S.E.M.

Figure 2. Upregulation of DEK is independent of proliferation. Proliferation of primary human CD34+ cells transduced with the indicated fusion genes, demonstrating that the upregulation of DEK is not a consequence of altered proliferation. Cell viability was consistently above 90% in all cultures. Mean values were calculated from three independent experiments. Error bars represent S.E.M.